Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Cash & Current Investments (2023 - 2025)

Mangoceuticals' Cash & Current Investments history spans 3 years, with the latest figure at $33899.0 for Q4 2025.

  • On a quarterly basis, Cash & Current Investments rose 100.09% to $33899.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $33899.0, a 100.09% increase, with the full-year FY2025 number at $33899.0, up 100.09% from a year prior.
  • Cash & Current Investments hit $33899.0 in Q4 2025 for Mangoceuticals, down from $498223.0 in the prior quarter.
  • Over the last five years, Cash & Current Investments for MGRX hit a ceiling of $1.2 million in Q3 2023 and a floor of $16942.0 in Q4 2023.
  • Historically, Cash & Current Investments has averaged $268637.1 across 3 years, with a median of $33899.0 in 2025.
  • The widest YoY moves for Cash & Current Investments: up 448.38% in 2025, down 96.54% in 2025.
  • Tracing MGRX's Cash & Current Investments over 3 years: stood at $16942.0 in 2023, then changed by 0.0% to $16942.0 in 2024, then skyrocketed by 100.09% to $33899.0 in 2025.
  • Business Quant data shows Cash & Current Investments for MGRX at $33899.0 in Q4 2025, $498223.0 in Q3 2025, and $16942.0 in Q2 2025.